Prime Highlights
- Biogen plans to acquire Apellis Pharmaceuticals in a $5.6 billion deal to expand its rare disease portfolio.
- The move aims to reduce reliance on its slowing multiple sclerosis business and boost near term growth.
Key Facts
- Biogen is a US based biotechnology company known for developing treatments for neurological and rare diseases.
- Apellis Pharmaceuticals is a biopharma company focused on therapies for rare diseases, including kidney, eye and blood disorders.
Background
Biogen has announced plans to acquire Apellis Pharmaceuticals in a deal valued at about $5.6 billion, as the company looks to strengthen its presence in rare diseases and expand beyond its slowing multiple sclerosis business. The announcement was made in April.
The acquisition marks one of the largest moves under CEO Chris Viehbacher, who is working to reshape the company’s growth strategy. Biogen has been under pressure after its Alzheimer’s treatment, Leqembi, saw lower than expected market uptake.
With this deal, Biogen will enter the kidney disease space and build stronger connections with specialists in this area. This could also support the future launch of its late-stage kidney drug, felzartamab.
Apellis brings two key medicines to the deal. Empaveli is approved for rare kidney diseases and a rare blood disorder, while Syfovre is used to treat an advanced eye condition that can lead to vision loss. The drugs achieved total revenue of approximately $689 million during the previous year, and business analysts predict their revenue will continue to increase in the upcoming years.
Under the agreement, Apellis shareholders will receive $41 per share in cash, along with possible additional payments linked to future sales of Syfovre. The offer represents a significant premium compared to the company’s recent stock price.
Market reaction was mixed. Apellis shares rose sharply, while Biogen shares fell. Analysts said the deal could boost Biogen’s near term revenue, though some expressed concern over the high price.
